Jennison Associates LLC lifted its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 12.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,992,711 shares of the biopharmaceutical company’s stock after buying an additional 437,437 shares during the quarter. Jennison Associates LLC’s holdings in CymaBay Therapeutics were worth $94,308,000 at […]
CymaBay Therapeutics, Inc (NASDAQ:CBAY) Receives Average Recommendation of Hold from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on CBAY. Piper Sandler reaffirmed a neutral rating and issued a $32.50 price target (down from $33.00) on shares […]
CymaBay Therapeutics (NASDAQ:CBAY) Now Covered by Analysts at StockNews com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […]